ARMONK, N.Y. - IBM today announced the formation of a new Watson Healthcare Advisory Board. The board members include medical leaders with expertise in areas such as primary care, oncology, biomedical informatics and medical innovation. They will provide IBM with insights on
healthcare issues that could be positively impacted by Watson technology adoption.

The advisory board will specifically focus on medical industry trends, clinical imperatives, regulatory considerations, privacy concerns, and
patient and clinician expectations around the Watson technology and how it can be incorporated into clinician workflows. The initial nine-member board represents leading organizations in various areas of healthcare delivery, and includes:
· Charles Barnett, Ascension Health, President, Healthcare Operations and Chief Operating Officer. Since 1993, Charles J.
Barnett FACHE, led the Seton Healthcare Family, an Ascension Health ministry, in serving the healthcare needs of 1.9 million Central Texas residents in 11 counties. Barnett now oversees
Ascension Health operations nationwide.
· Dr. Michael Barr, American College of Physicians ACP, Senior Vice President is responsible for promoting best practices according to the principles of patient-centered care and professionalism through the development of innovative products and services, quality improvement programs and educational initiatives for internists and other healthcare professionals.
· Dr. Herbert Chase, Columbia University Faculty, Professor of Clinical Medicine (in Biomedical Informatics) has collaborated with IBM Research on the Watson technology and related use cases in healthcare. Dr. Chase's research interests include decision
support tools for diagnosis and management of chronic kidney disease. He continues to develop new medical educational programs and is implementing a four-year curriculum in medical
decision-making.
· Dr. Lynda Chin, The University of Texas MD Anderson Cancer Center, Professor and Chair, Department of Genomic Medicine. Actively involved in the Cancer Genome Atlas (TCGA) and the
International Cancer Genome Consortium (ICGC), Dr. Chin is a recognized leader in the translation of the cancer genome. She is interested in using cutting-edged information technology and computational biology to accelerate the conversion of cancer genomic insights into tangible endpoints that impact patient outcome in the clinics.
· Chris Coburn, Cleveland Clinic, Executive Director of Innovation, has built a high performing team of nearly three dozen professionals in collaboration with some of the nation's top venture capitalists.

More HCB News